Joanna Sadowska: Bayer’s Asundexian Reduces Ischemic Stroke Risk in Phase 3 Trial
Joanna Sadowska, Biopharma Account Specialist, shared on LinkedIn:
”Big News – Bayer’s asundexian reduces ischaemic stroke risk in Phase 3 clinical trial
Bayer has announced positive Phase 3 results from the OCEANIC-STROKE study evaluating asundexian, an investigational once-daily oral Factor XIa inhibitor, for secondary stroke prevention.
This is the first study that successfully completed Phase 3 for Factor XIa.
Approximately 12 million people worldwide experience a stroke each year, with 20-30% being recurrent strokes.
One in five stroke survivors will have another stroke within five years, and these recurrent strokes tend to be more disabling and carry a higher mortality risk than first strokes.
Asundexian is a direct Factor XIa inhibitor designed to reduce thrombus formation that can lead to vessel blockage.
It has a novel mechanism targeting the coagulation pathway differently from current antiplatelet therapies.
Asundexian has received FDA Fast Track Designation for stroke prevention in this patient population.”
Stay informed with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda